BRIDGEWATER, N.J. - Insmed Incorporated (NASDAQ:INSM) announced today the appointment of Samuele Butera as Senior Vice President and General Manager of Global Respiratory, effective immediately, according to a press release statement.
Butera will lead Insmed’s Respiratory Therapeutic Area and report to Will Lewis, Chair and Chief Executive Officer. He will also serve on the company’s Executive Committee.
Butera brings over 20 years of commercial leadership experience in global and U.S. markets. He most recently served as President of Pulmonary Hypertension & Retina at Johnson & Johnson, where he led the launch of OPSYNVI. At Johnson & Johnson, he also held the position of Worldwide Vice President for Infectious Diseases & Vaccines, where he built the global commercial organization and co-led the company’s expansion into vaccines and therapeutics.
Prior to Johnson & Johnson, Butera held senior leadership roles at Novartis, including Global Head of Cell & Gene Therapies, where he led the worldwide launch of KYMRIAH, the first CAR-T therapy. He also served as Vice President & Head of Oncology CAR-T U.S. and Vice President & Head of North America for Sandoz Biopharmaceuticals.
Earlier in his career, Butera worked at McKinsey & Company, Goldman Sachs, and the United Nations. He holds a Master in Public Policy from Harvard University and a Bachelor of Science in International Economics from Università Bocconi in Milan, Italy.
Insmed is a biopharmaceutical company focused on therapies for serious diseases. The company’s commercial portfolio includes BRINSUPRI and ARIKAYCE, both approved therapies for lung diseases. The company is headquartered in Bridgewater, New Jersey, with offices in the United States, Europe, and Japan.With a market capitalization of $21.4 billion, Insmed posted revenue of $819.6 million over the last twelve months, reflecting impressive 115% growth. According to InvestingPro analysis, analysts anticipate continued sales growth this year, though the company remains unprofitable. The stock currently trades above its Fair Value, placing it among overvalued equities. For deeper insights, investors can access Insmed’s comprehensive Pro Research Report, available for this and 1,400+ other US stocks.
In other recent news, several investment firms have adjusted their outlook on Insmed. Mizuho lowered its price target for Insmed shares to $192 from $202, citing increased investor inquiries due to stock volatility and concerns ahead of the upcoming second-quarter results for Brinsupri. RBC Capital also reduced its price target to $195 from $205, maintaining an Outperform rating after discussions with Insmed management and a key opinion leader in respiratory disease. Truist Securities cut its price target to $185 from $205, adjusting its financial model in light of competitive risks and recent first-quarter results for 2026.
Meanwhile, BofA Securities reiterated a Buy rating with a $214 price target, highlighting the strong momentum of the Brinsupri launch and suggesting that the current stock pullback is overdone. Cantor Fitzgerald maintained an Overweight rating and a $235 price target, focusing on the potential of TPIP data in pulmonary arterial hypertension while noting the market’s current emphasis on Brinsupri. These updates reflect a range of perspectives on Insmed’s prospects, with firms weighing both competitive risks and the potential for market expansion.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.